Bloodstream infections and central line-associated bloodstream infections

• Published in: The Surgical clinics of North America Vol. 94; no. 6; p. 1233
• Main Authors: Watson, Christopher M, Al-Hasan, Majdi N
• Format: Journal Article
• Language: English
• Published: United States 01.12.2014
• Subjects: Anti-Bacterial Agents - therapeutic use; Bacteremia - diagnosis; Bacteremia - drug therapy; Bacteremia - etiology; Bacteremia - prevention & control; Catheter-Related Infections - diagnosis; Catheter-Related Infections - drug therapy; Catheter-Related Infections - etiology; Catheter-Related Infections - prevention & control; Cross Infection - diagnosis; Cross Infection - drug therapy; Cross Infection - etiology; Cross Infection - prevention & control; Humans; Infection Control - methods; Postoperative Complications - diagnosis; Postoperative Complications - drug therapy; Postoperative Complications - prevention & control; Bloodstream infection(s); Septicemia; Bacteremia; Catheter-related bloodstream infection(s)
• DOI: 10.1016/j.suc.2014.08.003

It is estimated that more than 575,000 individuals develop bloodstream infections (BSI) annually in North America, accounting for nearly 80,000 deaths. Central line-associated BSI (CLABSI) is a major contributor to the cost of health care. Although primary BSI may be seen by the surgeon, a secondary BSI is more likely to be encountered, especially CLABSI. Prompt identification of the source of infection in patients with secondary BSI is paramount. This practice allows early source control and initiation of appropriate antimicrobial therapy, with subsequent improvement in outcomes. An understanding of evidence-based preventative measures and bundles is important.